Contact
searchSearch
HMP Global
Login

Cognitive & Neurocognitive Disorders

Featured

quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
An illustrated face in profile, wearing a mask
News
Cognitive Deficits Observed in Aftermath of Both Short- and Long-COVID-19
03/07/2024
Brionna Mendoza
Cognitive deficits following COVID-19 infection, whether resolved after a short duration or longer-term persistence, have been confirmed through objective measurement.
Cognitive deficits following COVID-19 infection, whether resolved after a short duration or longer-term persistence, have been confirmed through objective measurement.
Cognitive deficits following...
03/07/2024
Neurology
From Neurology
Exercise Combined With Cognitive Training Could Delay Dementia Onset
News
Exercise Combined With Cognitive Training Could Delay Dementia Onset
08/09/2023
Evi Arthur
Aerobic-resistance exercise and computerized cognitive training could improve cognition in older adults with mild cognitive impairment, according to a randomized clinical trial published in JAMA Network Open. 
Aerobic-resistance exercise and computerized cognitive training could improve cognition in older adults with mild cognitive impairment, according to a randomized clinical trial published in JAMA Network Open. 
Aerobic-resistance exercise and...
08/09/2023
Neurology
From Neurology
News
CBT Identified as Effective First-Line Treatment for Insomnia in AUD Patients
07/28/2023
Tom Valentino
A study of veterans with alcohol use disorder found cognitive behavioral therapy outperformed sleep hygiene treatment in reducing insomnia, as well as alcohol consumption, cravings, and associated negative behaviors.
A study of veterans with alcohol use disorder found cognitive behavioral therapy outperformed sleep hygiene treatment in reducing insomnia, as well as alcohol consumption, cravings, and associated negative behaviors.
A study of veterans with alcohol...
07/28/2023
Addiction Professional
From Addiction Professional
quiz
Quiz
Parkinson Disease and Neurocognitive Disorder Comorbidity Rate
05/18/2023
About what percent of individuals diagnosed with Parkinson disease will eventually develop a major neurocognitive disorder (NCD), according to the DSM-5-TR? Take the quiz to find out!
About what percent of individuals diagnosed with Parkinson disease will eventually develop a major neurocognitive disorder (NCD), according to the DSM-5-TR? Take the quiz to find out!
About what percent of...
05/18/2023
Psych Congress Network
News
Women with PTSD Show Accelerated Cognitive Decline in Midlife
07/12/2022
Jolynn Tumolo
Post-traumatic stress disorder (PTSD) was associated with accelerated cognitive decline in middle-aged women, according to a large-scale prospective cohort study.
Post-traumatic stress disorder (PTSD) was associated with accelerated cognitive decline in middle-aged women, according to a large-scale prospective cohort study.
Post-traumatic stress disorder...
07/12/2022
Psych Congress Network
News
Healthier Diet Linked With Larger Brain Volume in Midlife
05/31/2022
Jolynn Tumolo
A higher quality diet is associated with larger brain volume during midlife, according to a study published in the Journal of Alzheimer’s Disease.
A higher quality diet is associated with larger brain volume during midlife, according to a study published in the Journal of Alzheimer’s Disease.
A higher quality diet is...
05/31/2022
Neurology
From Neurology
News
Neuropsychiatric Risk After COVID-19 On Par With Other Severe Respiratory Infections
05/25/2022
Jolynn Tumolo
Risks of new-onset neuropsychiatric disorders, such as anxiety and dementia, were similarly increased in adults surviving COVID-19 hospitalization and adults surviving hospitalization for other severe acute respiratory infections (SARI)...
Risks of new-onset neuropsychiatric disorders, such as anxiety and dementia, were similarly increased in adults surviving COVID-19 hospitalization and adults surviving hospitalization for other severe acute respiratory infections (SARI)...
Risks of new-onset...
05/25/2022
Psych Congress Network

News

An illustrated face in profile, wearing a mask
News
Cognitive Deficits Observed in Aftermath of Both Short- and Long-COVID-19
03/07/2024
Brionna Mendoza
Cognitive deficits following COVID-19 infection, whether resolved after a short duration or longer-term persistence, have been confirmed through objective measurement.
Cognitive deficits following COVID-19 infection, whether resolved after a short duration or longer-term persistence, have been confirmed through objective measurement.
Cognitive deficits following...
03/07/2024
Neurology
Exercise Combined With Cognitive Training Could Delay Dementia Onset
News
Exercise Combined With Cognitive Training Could Delay Dementia Onset
08/09/2023
Evi Arthur
Aerobic-resistance exercise and computerized cognitive training could improve cognition in older adults with mild cognitive impairment, according to a randomized clinical trial published in JAMA Network Open. 
Aerobic-resistance exercise and computerized cognitive training could improve cognition in older adults with mild cognitive impairment, according to a randomized clinical trial published in JAMA Network Open. 
Aerobic-resistance exercise and...
08/09/2023
Neurology
News
CBT Identified as Effective First-Line Treatment for Insomnia in AUD Patients
07/28/2023
Tom Valentino
A study of veterans with alcohol use disorder found cognitive behavioral therapy outperformed sleep hygiene treatment in reducing insomnia, as well as alcohol consumption, cravings, and associated negative behaviors.
A study of veterans with alcohol use disorder found cognitive behavioral therapy outperformed sleep hygiene treatment in reducing insomnia, as well as alcohol consumption, cravings, and associated negative behaviors.
A study of veterans with alcohol...
07/28/2023
Addiction Professional
News
Women with PTSD Show Accelerated Cognitive Decline in Midlife
07/12/2022
Jolynn Tumolo
Post-traumatic stress disorder (PTSD) was associated with accelerated cognitive decline in middle-aged women, according to a large-scale prospective cohort study.
Post-traumatic stress disorder (PTSD) was associated with accelerated cognitive decline in middle-aged women, according to a large-scale prospective cohort study.
Post-traumatic stress disorder...
07/12/2022
Psych Congress Network
News
Healthier Diet Linked With Larger Brain Volume in Midlife
05/31/2022
Jolynn Tumolo
A higher quality diet is associated with larger brain volume during midlife, according to a study published in the Journal of Alzheimer’s Disease.
A higher quality diet is associated with larger brain volume during midlife, according to a study published in the Journal of Alzheimer’s Disease.
A higher quality diet is...
05/31/2022
Neurology
News
Neuropsychiatric Risk After COVID-19 On Par With Other Severe Respiratory Infections
05/25/2022
Jolynn Tumolo
Risks of new-onset neuropsychiatric disorders, such as anxiety and dementia, were similarly increased in adults surviving COVID-19 hospitalization and adults surviving hospitalization for other severe acute respiratory infections (SARI)...
Risks of new-onset neuropsychiatric disorders, such as anxiety and dementia, were similarly increased in adults surviving COVID-19 hospitalization and adults surviving hospitalization for other severe acute respiratory infections (SARI)...
Risks of new-onset...
05/25/2022
Psych Congress Network
US FDA sign
News
FDA Approves Oveporexton for Adults With Narcolepsy Type 1
08/06/2026
Brionna Mendoza
The US FDA has approved oveporexton (ORZEYFUL), a first-in-class orexin treatment for narcolepsy type 1 (NT1) in adults.
The US FDA has approved oveporexton (ORZEYFUL), a first-in-class orexin treatment for narcolepsy type 1 (NT1) in adults.
The US FDA has approved...
08/06/2026
Psych Congress Network
FDA building
FDA Approval
FDA Approves Centanafadine for Pediatric and Adult ADHD
07/27/2026
Maria Mantas
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug...
07/27/2026
Psych Congress Network
illustration of a brain
Research Summary
Repeated Low-Dose Oral Esketamine Did Not Increase BDNF in Treatment-Resistant Depression
07/21/2026
Maria Mantas
Patients with TRD receiving repeated, low-dose oral esketamine did not experience greater increases in serum BDNF than those receiving placebo, according to study findings.
Patients with TRD receiving repeated, low-dose oral esketamine did not experience greater increases in serum BDNF than those receiving placebo, according to study findings.
Patients with TRD receiving...
07/21/2026
Psych Congress Network
FDA approval stamp
FDA Alerts
FDA Accepts NDA for AXS-12 in Cataplexy Associated With Narcolepsy
07/16/2026
Maria Mantas
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
The US Food and Drug...
07/16/2026
Psych Congress Network
Rakesh Jain, MD, MPH
Rapid Reaction
Rapid Reactions: Eli Lilly Acquisition Highlights Momentum in Psychedelics for Mental Health
07/16/2026
Rakesh Jain, MD, MPH, RD; Maria Mantas
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds...
07/16/2026
Psych Congress Network
a stethoscope, pills, and brain
Research Summary
Biobehavioral Markers May Improve Antidepressant Response in Major Depressive Disorder
07/16/2026
Maria Mantas
Patients with MDD and favorable biobehavioral markers for sertraline and/or bupropion experienced higher antidepressant response rates than those with negative markers for both drugs.
Patients with MDD and favorable biobehavioral markers for sertraline and/or bupropion experienced higher antidepressant response rates than those with negative markers for both drugs.
Patients with MDD and favorable...
07/16/2026
Psych Congress Network
an illustration of a man sitting on the ground holding his head with his profile and brain in the background
Research Summary
iTBS Offers Short-Term Improvement in Major Depressive Disorder
07/10/2026
Brionna Mendoza
A randomized clinical trial found that 10 once-daily sessions of iTBS produced short-term improvement compared to sham in clinician-rated depressive symptoms among adults with recurrent major depressive disorder (MDD).
A randomized clinical trial found that 10 once-daily sessions of iTBS produced short-term improvement compared to sham in clinician-rated depressive symptoms among adults with recurrent major depressive disorder (MDD).
A randomized clinical trial...
07/10/2026
Psych Congress Network
pills spilling out of a tipped over pill bottle
News
US Veterans Study Links SGLT2 Inhibitors to Lower Dementia Risk in Older Adults With Psychiatric Disorders
07/01/2026
Maria Mantas
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders. 
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders. 
Sodium-glucose cotransporter 2...
07/01/2026
Psych Congress Network
A patient sits across from a doctor who has a clipboard and is filling out a phone
Research Summary
Single-Dose LSD Formulation Hits Primary Endpoint in Phase 3 MDD Trial
06/29/2026
Brionna Mendoza
DT120, a proprietary formulation of lysergide (LSD) for treatment of MDD, met both primary and key secondary endpoints in the phase 3 Emerge study.
DT120, a proprietary formulation of lysergide (LSD) for treatment of MDD, met both primary and key secondary endpoints in the phase 3 Emerge study.
DT120, a proprietary formulation...
06/29/2026
Psych Congress Network
a young woman lies awake in bed
News
Adolescent Insomnia and Daytime Sleepiness Linked to Depression Risk
06/25/2026
Maria Mantas
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression. 
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression. 
A 3-year longitudinal study...
06/25/2026
Psych Congress Network

Quizzes

quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
quiz
Quiz
Parkinson Disease and Neurocognitive Disorder Comorbidity Rate
05/18/2023
About what percent of individuals diagnosed with Parkinson disease will eventually develop a major neurocognitive disorder (NCD), according to the DSM-5-TR? Take the quiz to find out!
About what percent of individuals diagnosed with Parkinson disease will eventually develop a major neurocognitive disorder (NCD), according to the DSM-5-TR? Take the quiz to find out!
About what percent of...
05/18/2023
Psych Congress Network
Chelsie Monroe Expert Insights Quiz
Expert Insights Quiz
Distinguishing EDS From Fatigue
08/03/2026
Maria Mantas
What key characteristics can help clinicians differentiate fatigue from excessive daytime sleepiness in clinical practice?
What key characteristics can help clinicians differentiate fatigue from excessive daytime sleepiness in clinical practice?
What key characteristics can...
08/03/2026
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Pharmacologic Treatment for Adolescent MDD
07/23/2026
Maria Mantas
Can you recall what the APA guideline recommends? Test yourself with this quick quiz!
Can you recall what the APA guideline recommends? Test yourself with this quick quiz!
Can you recall what the APA...
07/23/2026
Psych Congress Network
Craig Chepke, MD, DFAPA
Major Depressive Disorder Insights Quiz
Evaluating Anhedonia in MDD
07/22/2026
Maria Mantas
Why should clinicians think of anhedonia in major depressive disorder (MDD) as more than simply a loss of pleasure? Test your knowledge with this quiz!
Why should clinicians think of anhedonia in major depressive disorder (MDD) as more than simply a loss of pleasure? Test your knowledge with this quiz!
Why should clinicians think of...
07/22/2026
Psych Congress Network
an illustrated laptop screen displaying a quiz
Quiz
Patient Priorities in MDD Treatment
07/13/2026
Maria Mantas
Can you recall which symptom of MDD patients most wanted to see improved by treatment? Take the quiz!
Can you recall which symptom of MDD patients most wanted to see improved by treatment? Take the quiz!
Can you recall which symptom of...
07/13/2026
Psych Congress Network
Viloxazine MOA Study image
Quiz
Test Your Knowledge: New Study Clarifies Multimodal Mechanism of Viloxazine in ADHD
06/12/2026
New research suggests that viloxazine has a multimodal mechanism of action. Test your understanding with this short quiz.
New research suggests that viloxazine has a multimodal mechanism of action. Test your understanding with this short quiz.
New research suggests that...
06/12/2026
Psych Congress Network
Weight scale and tape measure
Quiz
Test Your Knowledge: Retrospective Cohort Study Explores Long-Term Growth Outcomes Following Pediatric Methylphenidate Use
06/12/2026
How well do you understand the relationship between pediatric attention-deficit/hyperactivity disorder, methylphenidate use in childhood, and growth outcomes in adulthood? Test your knowledge with this short, multiple-choice quiz.
How well do you understand the relationship between pediatric attention-deficit/hyperactivity disorder, methylphenidate use in childhood, and growth outcomes in adulthood? Test your knowledge with this short, multiple-choice quiz.
How well do you understand the...
06/12/2026
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Psilocybin Outcomes for MDD
06/11/2026
Brionna Mendoza
Test your knowledge of recent research with this quiz!
Test your knowledge of recent research with this quiz!
Test your knowledge of recent...
06/11/2026
Psych Congress Network
Desiree Matthews, PMHNP-BC
Quiz
Drug-Drug Considerations in TD Treatment
06/10/2026
Maria Mantas
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews,...
06/10/2026
Psych Congress Network
Desiree Matthews, PMHNP-BC
Quiz
Drug-Drug Considerations in TD Treatment
06/10/2026
Maria Mantas
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews,...
06/10/2026
Psych Congress Network
Girl in a classroom staring off into the distance
Quiz
Test Your Knowledge – Beyond the Stereotype: Rethinking Sex Differences in ADHD Presentation
05/12/2026
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation...
05/12/2026
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Desiree Matthews, PHMNP-BC; Amber Hoberg, MSN, APRN, PMHNP-BC
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use